A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmacokinetics and Pharmacodynamics"
DOI: 10.1007/s10928-018-9581-1
Abstract: Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area… read more here.
Keywords: exposure response; response; guselkumab dose; evaluation ... See more keywords